No Detail Found!

Comparative Analysis of Intravitreal Ranibizumab versus Laser Therapy for Retinopathy of Prematurity

Author(s)
Ahmed Elabbasy Division of Neonatology, Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Mona Abdelbaky Division of Neonatology, Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Hassan Al-Shehri Department of Pediatrics, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia
Ilene Padua Division of Neonatology, Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Ahmed Hamed College of Medicine, Alfaisal University, Riyadh, Saudi Arabi
Aladdin Kashlan College of Medicine, Alfaisal University, Riyadh, Saudi Arabi
Abdullah Alrobaie Department of Ophthalmology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Abdulrahman Albarqi Department of Ophthalmology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Ammar Aldawalibi Department of Ophthalmology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Amer Ammari Division of Neonatology, Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Fawaz Kashlan Division of Neonatology, Department of Pediatrics, Prince Sultan Military Medical City, Riyadh, Saudi Arabia
Abstract
The therapeutic effects of intravitreal Ranibizumab injection (IVR) and the efficacy of laser photocoagulation for the treatment of retinopathy of prematurity (ROP) are compared. The screening criteria for ROP were infants born with less than 32 weeks gestational period and/or weighed less than 1500 grams or unstable clinical course. After ethical approval from the Institutional Review Board, this retrospective study was conducted. The study considered 1315 infants and an observation was made that 36/42 (85.7%) eyes showed regression of ROP in the IVR group whereas 27/27 (100%) eyes that were treated with laser therapy showed regression of ROP (p=0.09). A considerable discrepancy in habituation of ROP in both groups with 12 eyes (28.6%) has been noted which is showing recurrence of ROP in the IVR group compared to 1 eye (3.7%) in the Laser group (P=0.01. In terms of anisometropia and refractive error, both groups made no notable difference. Squint was found remarkably higher in the laser group (29.6%) than in the IVR group (4.8%) (P=0.01). It was found that treating ROP eyes with laser treatment leads to greater improvement in infants than when treated by IVR. Moreover, a significant recurrence of ROP was discovered after IVR treatment in comparison with the laser treatment.
Publication Details
Page(s) 30-36
Published Journal: Archives of Pharmacy Practice, Volume: 13, Issue: 2, Year: 2022

Request the full text from PASTIC

Keywords
Vascular endothelial growth factor (VEGF), retinopathy, Ranibizumab, IVR treatment
0

Citations

0

Downloads

45

Views